medigraphic.com

2025, Number 4

<< Back Next >>

Enf Infec Microbiol 2025; 45 (4)

Advances in the Chlamydia trachomatis vaccine

Marriaga-Nuñez B, Cano-Bravo L, Solórzano-Santos F

Language: Spanish
References: 23
Page: 197-202
PDF size: 187.87 Kb.


ABSTRACT

Chlamydia trachomatis (Ct ) is an obligate intracellular, gram-negative bacterium considered the leading cause of sexually transmitted infections (STIS). The World Health Organization (WHO) reported that in 2020, Ct caused approximately 128.5 million new sti cases worldwide in people aged 15 to 49 years. In women, a high percentage of Ct infections are often asymptomatic, favoring repeated infections that carry a higher risk of pelvic inflammatory disease. The sustained inflammatory microenvironment leads to tubal pathology, with chronic pain, ectopic pregnancies, and infertility due to tubal damage. The incidence of Ct infection in Mexican women ranges between 3 and 13%.
sti prevention programs have been ineffective, particularly with Ct . There is a high prevalence, relatively ineffective screening programs, and a high frequency of asymptomatic infections with significant morbidity in women and their unborn children. Therefore, there is an urgent need to develop more effective prevention strategies. Vaccination should be considered as a possibility. To date, no vaccines against Chlamydia trachomatis have been marketed, and all are in different stages of evaluation. This document presents some of the advances in vaccine development.


REFERENCES

  1. Aaron, K.J., Gaydos, C.A.,, Hook E.W. 3rd, Chernesky, M.,Moncada, J., Taylor, S.N., Wiesenfeld, H.C., Mayer, K.H.,Golden, M.R., Boutwell, A. y Van Der Pol, B., “Chlamydiaand gonorrhea infections in genital and extragenitalsamples among men and women”, Sex Transm Dis, 2025. doi: 10.1097/OLQ.0000000000002154.

  2. Sánchez Navarro, J.P., Barriga Angulo, G., Mata Marín,J.A., Rodríguez Evaristo, M., Padilla Noguera, P.E. yGaytán Martínez, J.E., “High prevalence of asymptomaticstis in msm pwh in a male hiv clinic in Mexico City”, J IntAssoc Provid aids Care, 2025, 24: 23259582251321039.

  3. McCullough, A., Huang, S. y Weber, M.M., “Pathogenicityand virulence of Chlamydia trachomatis: insightsinto host interactions, immune evasion, and intracellularsurvival”, Virulence, 2025, 16 (1): 2503423.

  4. Den Heijer, C.D.J., Hoebe, C.J.P.A, Driessen, J.H.M.,Wolffs, P., Van den Broek, I.V.F., Hoenderboom, B.M.,Williams, R., De Vries, F. y Dukers-Muijrers, N.H.T.M.,“Chlamydia trachomatis and the risk of pelvic inflammatorydisease, ectopic pregnancy, and female infertility:a retrospective cohort study among primary carepatients”, Clin Infect Dis, 2019, 69 (9):1517-1525. Errataen: Clin Infect Dis, 2020, 70 (11): 2459.

  5. Muñiz-Salgado, J.C., Hurtado-Arroyo, R.B., García-Cisneros,S., Olamendi-Portugal, M., Sánchez-Aleman,M.A., Vergara-Ortega, D.N. y Herrera-Ortiz, A., “Prevalenceof Chlamydia trachomatis and associated factorsin pregnant adolescent and young adult females fromMorelos, Mexico: a cross-sectional study”, Int J std aids,2025, 36 (9): 705-711.

  6. Escobedo-Guerra, M.R., López-Hurtado, M., Gutiérrez-Trujillo, R. y Guerra-Infante, F.M., “Prevalencia deChlamydia trachomatis en mujeres del Hospital Generalde Zona No. 29”, Rev Med Inst Mex Seguro Soc, 2021,59 (4): 281-289.

  7. O’Connell, C.M. y Ferone, M.E., “Chlamydia trachomatisgenital infections”, Microb Cell, 2016, 3 (9): 390-403.

  8. Elwell, C., Mirrashidi, K. y Engel, J., “Chlamydia cell biologyand pathogenesis”, Nat Rev Microbiol, 2016, 14(6): 385-400.

  9. Stallmann, S. y Hegemann, J.H., “The Chlamydia trachomatisCtad1 invasin exploits the human integrin β1receptor for host cell entry”, Cell Microbiol, 2016, 1 (5):761-775.

  10. Ridderhof, J.C. y Barnes, R.C., “Fusión de inclusionestras la superinfección de células hela con dos serovaresde Chlamydia trachomatis”, Infect Immun, 1989, 57,3189-3193.

  11. Hackstadt, T., Baehr, W. y Ying, Y., “Chlamydia trachomatisdevelopmentally regulated protein is homologous toeukaryotic histone H1”, Proc Natl Acad Sci USA, 1991,88 (9): 3937-3941.

  12. Hybiske, K. y Stephens, R.S., “Mechanisms of host cellexit by the intracellular bacterium Chlamydia”, Proc NatlAcad Sci USA, 2007, 104 (27): 11430-1435.

  13. Huang, S., Carnevale, C., Neu, N., Klein, J., Quigee,D., Pérez, E., Burrell, L., Meyers, K., McLean, J., Sobieszczyk,M.E., Castor, D. y Zucker, J., “Implementationof doxy-pep in a diverse sexual health program in NorthernManhattan: the Doxy-Care Study”, Am J PublicHealth, 2025: e1-e5.

  14. Dong, S., Duval, M.X., Do, T.D., Ho, J., Abdallah, O.,White, M.R., Johnson, J.C., Meda, C. y Schoenbrunner,N., “A rapid multiplex lamp assay for point-of-care detectionof ct, ng, tv, and fluoroquinolone resistance in ng”,bioRxiv, 2025: 2025.07.24.666671.

  15. Narváez, S., Arnalda, N., López, M., Vergara, A., Guilera,V., Chivite, I., García-Hernández, D., González-Cordón,A., Riera-Monroig, J., Fuertes, I., Mallolas, J., Blanco,J.L. y Bosch, J., “Detection of Neisseria gonorrhoeaeand Chlamydia trachomatis by pcr in a sample pool(urine, rectum and pharynx) in asymptomatic patients atrisk of sexually transmitted infections”, Enferm InfeccMicrobiol Clin (Inglaterra), 2025, 43 (7): 374-377.

  16. Geisler, W.M., Wang, C., Morrison, S.G, et al., “The naturalhistory of untreated Chlamydia trachomatis infectionin the interval between screening and returning fortreatment”, Sex Transm Dis, 2008, 35 (2): 119-123.

  17. Sun, G., Pal, S., Weiland, J. et al., “Protection against anintranasal challenge by vaccines formulated with nativeand recombinant preparations of the Chlamydia trachomatismajor outer membrane protein”, Vaccine, 2009,27 (36): 5020-5025.

  18. Phillips, S., Quigley, B.L. y Timms, P., “Seventy yearsof chlamydia vaccine research: limitations of the pastand directions for the future”, Front Microbiol, 2019, 10:433459.

  19. Pollock, K.M., Borges, Á.H., Cheeseman, H.M. et al.,“An investigation of trachoma vaccine regimens by thechlamydia vaccine cth522 administered with cationicliposomes in healthy adults (chlm-02): a phase 1, double-blind trial”, Lancet Infect Dis, 2024, 24 (8): 829-844.

  20. Bettin, L., Stadler, M., Unterweger, C., Dippel, M., Harris,J.M., Buzanich-Ladinig, A., Poston, T.B., Darville, T. yKäser, T., “A cyclic-di-amp adjuvanted cpaf protein vaccineis immunogenic in swine, but it fails to reduce genitalChlamydia trachomatis burden”, Vaccines (Basilea),2025, 13 (5): 468.

  21. Jamus, A.N., Wilton, Z.E.R., Armijo, S.D., Flanagan, J.,Romano, I.G., Core, S.B. y Frietze, K.M., “Nasal and ocularimmunization with bacteriophage virus-like particlevaccines elicits distinct systemic and mucosal antibodyprofiles”, Vaccines (Basilea), 2025, 13 (8): 829.

  22. Babu Sait, M.R., Jachmann, L.H., Türköz, G., Milivojevic,M., Llorente-Sáez, C., Dhanjal, S. et al., “Genome-wideidentification of modulators of Chlamydia trachomatisparasitophorous vacuole stability highlights an importantrole for sphingolipid supply”, plos Biol, 2025, 23 (8):e3003297.

  23. McCullough, A., Huang, S. y Weber, M.M., “Pathogenicityand virulence of Chlamydia trachomatis: insightsinto host interactions, immune evasion, and intracellularsurvival”, Virulence, 2025, 16 (1): 2503423.




2020     |     www.medigraphic.com